Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To determine the maximum tolerated dose of the combination of cisplatin, imatinib
mesylate, and pemetrexed in metastatic malignant mesothelioma.
Secondary Objectives:
- To explore the biologic effects of cisplatin, imatinib mesylate, and pemetrexed on tumor
tissue by:
- histologic analysis of biopsy tissue
- by non-invasive assessments of tumor vascularity performed before, during and after
treatment
- electron microscopy analysis of endothelial cell architecture after patient treatment
with imatinib mesylate
- To explore the effects of cisplatin, imatinib mesylate, and pemetrexed on surrogate
markers in serum.
- To assess the rate of response to therapy.
- To determine the doses of the combination regimen of cisplatin, imatinib mesylate, and
pemetrexed that enables de-phosphorylation of platelet derived growth factor receptor
(PDGF-R) on malignant mesothelioma tumor cells.
- To determine the pharmacokinetic interaction between agents in this combination regimen.